Chemotherapy with mitoxantrone liposome before stem cell transplant for AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a stronger pre-transplant conditioning regimen—using a liposome form of mitoxantrone with standard chemotherapy—to help wipe out remaining AML cells before a stem cell transplant. It is for people with higher-risk AML or who still have measurable disease before transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 60 years.
- Diagnosed with acute myeloid leukemia (AML), but not a subtype called acute promyelocytic leukemia.
- Either have intermediate or high-risk AML, or still have measurable cancer cells (minimal residual disease) before transplant.
- Must be generally well enough (able to do daily activities) with a performance score of 0 to 2.
- No serious heart problems, active liver or kidney failure, or uncontrolled infections.
- Must be HIV-negative and not have active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This study tests a combination treatment called VMAC (a chemotherapy) plus DLI (donor immune cells) for people whose AML has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia again.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.